Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Minority Interest (2022 - 2025)

MoonLake Immunotherapeutics' Minority Interest history spans 4 years, with the latest figure at $2.3 million for Q3 2025.

  • Quarterly Minority Interest fell 68.73% to $2.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Sep 2025, down 68.73% year-over-year, with the annual reading at $6.6 million for FY2024, 63.14% down from the prior year.
  • Minority Interest came in at $2.3 million for Q3 2025, down from $4.2 million in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $64.7 million in Q3 2023 to a low of $2.3 million in Q3 2025.
  • The 4-year median for Minority Interest is $9.6 million (2024), against an average of $16.6 million.
  • Year-over-year, Minority Interest skyrocketed 137.2% in 2023 and then tumbled 88.71% in 2024.
  • MoonLake Immunotherapeutics' Minority Interest stood at $19.9 million in 2022, then fell by 10.33% to $17.8 million in 2023, then plummeted by 63.14% to $6.6 million in 2024, then crashed by 65.2% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for MLTX's Minority Interest are $2.3 million (Q3 2025), $4.2 million (Q2 2025), and $5.1 million (Q1 2025).